Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Drive2 Aug. 21 at 9:38 PM

$KALA oxervate did $1.2B last year. They are a private company out of Italy. And their treatment only acount for 1/3 of what kpi-012 can service. I bet they are watching this VERY closely and may take a shot at buying upon the results.

0 · Reply

LuckyGambler69 Aug. 21 at 3:47 PM

$KALA Check TNON👀🍀

0 · Reply

ferrisss Aug. 21 at 9:09 AM

$KALA do u think trial results could be priced in around 9 and go back to $4? Just asking.

2 · Reply

Drive2 Aug. 19 at 9:51 PM

$KALA how this isn't already trading at 15 per share ? If results are strong it should rockets. 3B in potential sales estimates. And they said thats conservative. W a 50mm current market cap - investors are completely asleep on this

2 · Reply

Drive2 Aug. 19 at 9:49 PM

$KALA interesting swing today on 150k shares. Release the dang results early!!! You guys are already almost a year late anyway. C'mon.

0 · Reply

StockScanners Aug. 19 at 12:43 AM

$KALA reached 8.75

0 · Reply

JazsminC Aug. 18 at 1:59 PM

$KALA Approaching 9 slow and steady

1 · Reply

StockScanners Aug. 16 at 3:28 AM

$KALA keep watch if this holds above 7.85

0 · Reply

Drive2 Aug. 13 at 6:01 PM

$KALA 1 more month it seems. Buying opportunity at these levels imho.

0 · Reply

JazsminC Aug. 13 at 5:20 PM

$KALA

0 · Reply

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 15 days ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 6 weeks ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 3 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 6 months ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 8 months ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 9 months ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 1 year ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 1 year ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 2 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 19, 2023, 7:12 AM EST - 2 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Dec 30, 2022, 12:02 PM EST - 2 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 2 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 2 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 2 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 2 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 3 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 12:01 AM EDT - 3 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 10:54 AM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:00 AM EDT - 3 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 2, 2022, 1:25 PM EDT - 3 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 1, 2022, 9:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Apr 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Mar 29, 2022, 12:10 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q4 2021 Results - Earnings Call Transcript

Mar 29, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Drive2 Aug. 21 at 9:38 PM

0 · Reply

LuckyGambler69 Aug. 21 at 3:47 PM

$KALA Check TNON👀🍀

0 · Reply

ferrisss Aug. 21 at 9:09 AM

$KALA do u think trial results could be priced in around 9 and go back to $4? Just asking.

2 · Reply

Drive2 Aug. 19 at 9:51 PM

2 · Reply

Drive2 Aug. 19 at 9:49 PM

$KALA interesting swing today on 150k shares. Release the dang results early!!! You guys are already almost a year late anyway. C'mon.

0 · Reply

StockScanners Aug. 19 at 12:43 AM

$KALA reached 8.75

0 · Reply

JazsminC Aug. 18 at 1:59 PM

$KALA Approaching 9 slow and steady

1 · Reply

StockScanners Aug. 16 at 3:28 AM

$KALA keep watch if this holds above 7.85

0 · Reply

Drive2 Aug. 13 at 6:01 PM

$KALA 1 more month it seems. Buying opportunity at these levels imho.

0 · Reply

JazsminC Aug. 13 at 5:20 PM

$KALA

0 · Reply

Lwschadler Aug. 12 at 4:13 PM

$KALA Up up up!

0 · Reply

ferrisss Aug. 12 at 10:32 AM

$KALA Once it has beaten Q2 EPS estimate, this only needs a spark to fly as it did in 2022. Someone buying big or the expected results in September, whatever.

2 · Reply

ferrisss Aug. 8 at 8:14 PM

$PSTV $BTAI $KALA my plays for the rest of the month

1 · Reply

Tradingforfunz Aug. 8 at 5:17 PM

$KALA Swing

0 · Reply

d_risk Aug. 8 at 2:45 PM

$KALA - KALA BIO, Inc. - 10Q - Updated Risk Factors KALA flags deepening losses, urgent need for new funding, heavy dependence on KPI-012 amid clinical and regulatory hurdles, supply chain and tariff risks, expanded competition, reliance on partners, evolving patent and pricing threats, new compliance and cybersecurity risks, and warns it may not survive without more capital. #Biotechnology #RegulatoryCompliance #SupplyChain #FundingRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/KALA/10-Q/2025-08-08

2 · Reply

Drive2 Aug. 8 at 2:37 AM

$KALA if results are strong and they don't need another trial. What are your price predictions? And predictions w another trial needed.

1 · Reply

JazsminC Aug. 7 at 3:52 PM

$KALA Slow week, but at least its giving me some chances to accumulate. Honestly, companies should invest more in eye health, since everywhere we go we look at screens..

2 · Reply

Drive2 Aug. 6 at 11:24 PM

$KALA oxercate did 1.2 B in sales last year. And that's 1/3 of what kpi- 012 can do. IF results are good w a market cap of only 50m and low low float. Man.

0 · Reply

Drive2 Aug. 6 at 11:23 PM

$KALA and how an update on KPI- 014

0 · Reply

Drive2 Aug. 6 at 11:22 PM

$KALA KPI- 012 results please!

0 · Reply

LegendaryCharts Aug. 6 at 10:55 PM

$KALA

0 · Reply

ferrisss Aug. 6 at 6:17 PM

$KALA looks like nobody knows when they'll release earnings, since I've seen different dates on different websites: 8/4, 8/5, 8/13, 8/19.

0 · Reply

Market Cap	58.91M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-10.32

Volume	105,560
Avg Vol	141,408
Day's Range	N/A - N/A
Shares Out	7.02M
Stochastic %K	76%
Beta	-1.81
Analysts	Strong Sell
Price Target	$13.00